Get the Stockscreener App
5.74
11.24%
0.58
Verve Therapeutics Inc stock is traded at $5.74, with a volume of 3.66M.
It is up +11.24% in the last 24 hours and up +26.15% over the past month.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$5.16
Open:
$5.12
24h Volume:
3.66M
Relative Volume:
2.53
Market Cap:
$485.97M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-1.8107
EPS:
-3.17
Net Cash Flow:
$-134.39M
1W Performance:
+0.53%
1M Performance:
+26.15%
6M Performance:
+11.89%
1Y Performance:
-57.73%
1-Day Range:
$5.12
$5.76
1-Week Range:
$4.88
$5.76
52-Week Range:
$4.305
$19.34
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Compare VERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
5.74 | 485.97M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-24 | Initiated | H.C. Wainwright | Buy |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - The Eastern Progress Online
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - The Eastern Progress Online
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
2024-12-18 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation - AccessWire
Verve Therapeutics Slides As Insider Purchases Lose Another US$65k - Yahoo Finance
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online
Charles Schwab Investment Management Inc. Increases Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out - AccessWire
2024-12-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out | NDAQ:VERV | Press Release - Stockhouse Publishing
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact The Gross Law Firm - Victoria Advocate
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com Australia
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - The Eastern Progress Online
Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - The Eastern Progress Online
103,348 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Purchased by XTX Topco Ltd - MarketBeat
Pixalate Releases Q3 2024 EMEA Supply-Side Platform (SSP) Market Share Rankings for Connected TV (CTV), Mobile Apps, & Web: Magnite Leads CTV in Germany (65%) on Amazon Fire TV, Verve No. 1 on Mobile (57%) in Google Play Store - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - The Eastern Progress Online
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - The Eastern Progress Online
Faruqi & Faruqi Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - The Eastern Progress Online
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - The Eastern Progress Online
(VERV) On The My Stocks Page - Stock Traders Daily
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Simply Wall St
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
Jacobs Levy Equity Management Inc. Increases Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Redmile Group LLC Sells 80,040 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Verve Therapeutics: Cutting-Edge Science But Highly Risky Stock - Seeking Alpha
PDT Partners LLC Decreases Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verve Therapeutics Inc Stock (VERV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):